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To examine whether a higher body mass index (BMI) in
kidney recipients is associated with delayed graft function
(DGF), we analyzed data from 11,836 hemodialysis patients in
the Scientific Registry of Transplant Recipients who
underwent kidney transplantation. The patient cohort
included women, blacks, and diabetics; the average age
was 49 years; and the mean BMI was 26.8 kg/m2. After
adjusting for relevant covariates, multivariate logistic
regression analyses found that one standard deviation
increase in pretransplant BMI was associated with a higher
risk of DGF (odds ratio (OR) 1.35). Compared with patients
with a pretransplant BMI of 22–24.99 kg/m2, overweight
patients (BMI 25–29.99 kg/m2), mild obesity patients
(BMI 30–34.99 kg/m2), and moderate-to-severe obesity
patients (BMI 35kg/m2 and over) had a significantly higher
risk of DGF, with ORs of 1.30, 1.42, and 2.18, respectively.
Similar associations were found in all subgroups of patients.
Hence, pretransplant overweight or obesity is associated with
an incrementally higher risk of DGF.
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Delayed graft function (DGF) is a well-known complication
affecting kidney allograft outcomes in the immediate post-
transplantation period and is defined as the need for at least
one session of dialysis treatment in the first week after
receiving a kidney transplant;1 DGF is attributed to ischemia
reperfusion and immunological injury of the graft.2 The
prevalence of DGF varies from 4 to 10% in living donor2 and
5–50% in deceased donor kidney transplants.3–7 The
occurrence of DGF may significantly complicate the im-
mediate post-transplant management by increasing morbid-
ity and mortality,8,9 prolonging patient hospitalization,10 and
inflating health care costs.10–12
Overweight (body mass index (BMI) 25-o30 kg/m2) and
obesity (BMI430 kg/m2) at the time of kidney transplanta-
tion are common among North American dialysis patients.13
Pretransplant obesity may have differential effects on short-
versus long-term post-transplant outcomes. Some studies
report poorer long-term post-kidney transplant outcomes in
obese dialysis patients14–17 mainly due to cardiovascular
complications,18 whereas other studies have found no
association between pretransplant BMI and long-term post-
transplant outcomes,19–22 including our recent study in10,090
kidney transplant recipients.23 In contrast, pretransplant
obesity is usually associated with such untoward short-term
complications, such as surgical wound infections or dehis-
cence.24 More recent studies report that obese renal
transplant recipients have higher risk of developing diabetes
mellitus or diverse postoperative complications.19,22,24–26
However, it is not known whether overweight or obesity
has a negative impact on other short-term complications, in
particular DGF. To the best of our knowledge, only a small
case–control study (n¼ 80) by Espejo et al.27 showed that
obese patients have higher risk of DGF after kidney
transplantation, whereas Yamamoto et al.28 (n¼ 28) found
no meaningful association between obesity and DGF. Obesity
is associated with higher sympathetic activity,29,30 which
along with imminent administration of calcineurin inhibitors
may lead to renal vasoconstriction and decreased kidney
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perfusion, resulting in DGF. Moreover, obesity is associated
with longer operative time and longer ischemic time,31 which
is associated with elevated risk of DGF.32,33 Given these
biologically plausible hypotheses and the foregoing incon-
sistent data, we sought to examine whether recipients’ high
BMI has a bearing on early post-transplant graft function in a
large and contemporary, incident cohort of kidney transplant
recipients throughout the United States. We hypothesized
that higher pretransplant BMI during the months immedi-
ately before kidney transplantation is associated with higher
prevalence of DGF in post-transplant patient.
RESULTS
The original 5-year (July 2001–June 2006) national database
of all DaVita dialysis patients included 164,789 adult subjects.
This database was linked via unique identifiers to the national
Scientific Registry of Transplant Recipients (SRTR) registry
that included all transplant waitlisted people and kidney
transplant recipients until June 2007 (Figure 1). Out of
37,766 DaVita dialysis patients who were identified in the
SRTR database, 17,629 had undergone one or more kidney
transplantations during their life time, including 14,508
patients who had undergone their first kidney transplanta-
tion between July 2001 and July 2007. After excluding those
without electronically recorded data (n¼ 1), peritoneal
dialysis patients (n¼ 2092), subjects who lacked data from
baseline quarter, or those with outlier values for age (499 or
o16 years; n¼ 579), there were 11,836 hemodialysis patients
who met all inclusion and exclusion criteria and who
subsequently underwent their first kidney transplantation
during the observation period.
Table 1 compares the demographic, clinical, transplant-
related, and pretransplant laboratory characteristics of the
patients with (n¼ 2628) and without (n¼ 9208) DGF.
Patients with DGF were 2 years older and more likely to be
diabetic or African American or to have Medicare as their
primary insurance. Patients with DGF had lower serum
albumin and hemoglobin levels and were more likely to
receive kidneys from deceased donors with longer cold
ischemic time. Additionally, patients with DGF had a higher
pretransplant BMI by 1.2 kg/m2 than those without DGF
(Table 1).
Table 2 shows the results of multivariate logistic regression
analyses. Pretransplant BMI was an important predictor of
DGF in univariate analysis. One s.d. (s.d.¼ 6.0 kg/m2)
increase of pretransplant BMI was associated with 30%
higher risk of DGF (odds ratio (OR)¼ 1.30; 95% confidence
interval (CI): 1.24–1.36). The association between pretrans-
plant BMI and the risk of DGF in the entire cohort are shown
in Figure 2 and Supplementary Figure S1 in the Appendix
online. After adjusting for case mix and malnutrition–in-
flammation complex syndrome variables, pretransplant BMI
remained an independent and significant predictor of DGF
(Table 2). This association remained significant after
adjusting for transplant-related variables: 1 s.d. increase of
pretransplant BMI was associated with a 35% higher risk of
DGF (OR¼ 1.35; 95% CI: 1.27–1.45). Compared with
patients with pretransplant with BMI in high normal range
(22–24.99 kg/m2), the patient groups with overweight
(25–29.99 kg/m2), mild obesity (30–34.99 kg/m2), and mod-
erate-to-severe obesity (X35 kg/m2) had 30, 42, and 118%,
respectively, higher risk of DGF in the fully adjusted model
37,766 DaVita MHD patients from 07/2001 to 06/2006
were identified in the SRTR database ending 06/2007
17,629 Renal transplant recipients
14,736 Renal transplant recipients
14,508 Renal transplant recipients
12,415 Renal transplant recipients
11,836 Renal transplant recipients
Excluding waitlisted but not yet
transplanted (n =20,137)
Exclude patients who were
transplanted more than once
(n =228 patients excluded)
Exclude subjects on PD (n=2092)
or patients who do not have DGF data
(n =1)
Exclude if age not within 16–99
years (n =579)
Restrict to transplant dates
between 07/2001 and 06/2007
(n =2893)
Figure 1 | Flow chart of the patient selection (see text). DGF, delayed graft function; MHD, maintenance hemodialysis; PD, peritoneal
dialysis; SRTR, Scientific Registry of Transplant Recipients.
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(Po0.05; Figure 2). Patients with pretransplant BMI higher
than 35 kg/m2 had 87% higher risks of DGF than individuals
with pretransplant BMI lower than 35 kg/m2 (OR¼ 1.87;
95% CI: 1.52–2.30). Qualitative similar results were found
when different cutoff points for BMI were used (Table 2). The
association of BMI with DGF was monotonously incremental
when BMI was modeled as a continuous variable and using
fractional polynomials and cubic splines (Supplementary
Figure S1 online). These associations persist in sensitivity
analyses including after inclusion of peritoneal dialysis
patients (Supplementary Figure S2 online).
Similar associations were observed in all subgroups.
Figure 3 shows fully adjusted OR (and 95% CI) of DGF
associated with each s.d. higher pretransplant BMI across
various patient subgroups. The OR of DGF across all
examined subgroups was 41, indicating a higher risk. Most
interaction tests did not exhibit small P-values, indicating
lack of major effect modification by the examined character-
istics, except for diabetes and extended donor criteria. The
association between pretransplant BMI and DGF was
stronger in non-diabetic patients and in recipients of an
extended donor criteria kidney (Supplementary Table S1
online). Of note, in deceased donor subgroup, each s.d.
increase of BMI was associated with 36% risk of DGF (OR
(95% CI): 1.36 (1.26–1.46)). In living donor subgroup, each
s.d. increase of BMI was associated with 33% (OR (95% CI):
1.33 (1.14–1.56)) risk of DGF. The interaction term was not
significant (P¼ 0.88; Supplementary Table S1 online).
DISCUSSION
In 11,836 kidney transplant recipients with comprehensive
pre- and post-transplant data, higher pretransplant BMI
during the last calendar quarter of hemodialysis treatment
was associated with higher risk of DGF during the first post-
transplant week. Compared with patients with pretransplant
BMI between 22 and 24.99 kg/m2, the overweight and obese
patients with higher pretransplant BMI (25–29.99 kg/m2,
30–34.99 kg/m2, and X35 kg/m2) had incrementally higher
risk, that is, 30, 42, and 118% higher risk of DGF, whereas
lower BMI o22 kg/m2 tended to show B25% lower DGF
risk. The associations between pretransplant BMI and DGF
were rather consistent across diverse demographic, clinical,
and laboratory subgroups. These finding may have important
implications for pretransplant management of waitlisted
patients.
DGF is a common short-term post-transplant complica-
tion and occurs in 5–50% of all kidney transplant recipients.
It is especially more frequent with deceased donor kidneys.3–6
The well-known deleterious effects of DGF in the immediate
post-transplant period are multiple and include complica-
tions of the immediate post-transplant patient care in the
hospital. However, there may be even long-term impact of
DGF. Most,34,35 but not all,36,37 studies report an association
between DGF and reduced long-term graft survival rate. A
systematic review reported that DGF is associated with a 41%
increased risk of graft loss,8 38% increased risk of acute
rejection in the first year, and a higher serum creatinine
concentration at 3.5 years of follow-up.8
Overweight and obesity are highly prevalent at the time of
kidney transplantation.13 Previous reports have described
Table 1 | Demographic, clinical, and laboratory characteristics
for 11,836 long-term hemodialysis patients who received
kidney transplants
Variable All With DGF Without DGF P-value
N (%) 11,836 (100) 2628 (22.2) 9208 (77.8) NA
Age (years) 49±14 50±13 48±14 o0.001
Gender (% women) 38 34 39 o0.001
Diabetes mellitus (%) 26 29 26 o0.001
Race/ethnicity (%)
Whites 46 39 48 o0.001
African Americans 27 35 25 o0.001
Hispanics 14 14 14 0.85
Asians 4 3 4 0.01
Dialysis vintage time (%)
o6 months 12 6 14 o0.001
6–24 months 28 19 31 o0.001
2–5 years 36 41 35 o0.001
45 years 24 34 21 o0.001
Primary insurance (%)
Medicare 52 59 50 o0.001
Medicaid 3 3 3 0.47
Private insurance 16 14 17 0.003
Other 20 14 22 o0.001
Marital status (%)
Married 47 46 48 0.26
Divorced 6 6 6 0.65
Single 27 28 27 0.17
Widowed 3 3 3 0.98
BMI (kg/m2) 26.8±6.0 28.0±6.7 26.4±5.7 o0.001
Kt/V (dialysis dose) 1.61±0.35 1.60±0.33 1.62±0.36 0.055
nPCR (g/kg/day) 1.05±0.25 1.06±0.25 1.05±0.26 0.01
Serum albumin (g/dl) 4.02±0.37 4.00±0.37 4.03±0.38 o0.001
Creatinine (mg/dl) 10.6±3.2 11.1±3.1 10.5±3.2 o0.001
Bicarbonate (mg/dl) 21.9±3.4 22.2±3.3 21.8±3.4 o0.001
TIBC (mg/dl) 212±40 208±39 213±41 o0.001
Ferritin (ng/ml)a 469 (249–731) 534 (299–786) 448 (236–717) o0.001
Phosphorus (mg/dl) 5.95±1.54 5.97±1.57 5.94±1.53 0.41
Calcium (mg/dl) 9.43±0.74 9.42±0.77 9.44±0.73 0.23
Blood hemoglobin (g/dl) 12.3±1.2 12.2±1.3 12.3±1.2 0.001
WBC ( 103/l) 6.8±2.0 6.9±2.1 6.8±2.1 0.24
Lymphocyte (% total of WBC) 23±8 23±8 23±8 0.22
Pretransplant transfusion (%) 31 36 30 o0.001
Number of HLA mismatches 4 (3–5) 4 (2–5) 4 (3–5) o0.001
PRA (%)a 0 (0–3) 0 (0–4) 0 (0–3) 0.21
Cold ischemia time (hours)a 14 (4–22) 19 (12–25) 12 (2–20) o0.001
EDC kidney (%) 19 23 17 o0.001
Donor type (% of living) 32 10 38 o0.001
Donor age (years) 39±15 42±15 38±15 o0.001
Abbreviations: BMI, body mass index; DGF, delayed graft function; EDC, extended
donor criteria; HLA, human leukocyte antigen; IQR, interquartile range; NA, not
available; nPNA, normalized protein nitrogen appearance; PRA, panel reactive
antibody (last value before transplant); TIBC, total iron-binding capacity; WBC, white
blood cell.
aMedian (IQR).
Data are from the last or second-to-last calendar quarter before transplantation.
Values are in percentage or mean±s.d. or median (IQR), as appropriate.
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conflicting associations between BMI and various outcomes
in kidney transplant recipients. Early studies showed higher
risk of postoperative complications31 and early surgical
wound infections24 in obese patients. Lentine et al.18 reported
higher incidence of cardiovascular event, including heart
failure and atrial fibrillation, and early postoperative
complications in obese versus non-obese patients. Several
other studies, however, did not find any association between
pretransplant BMI and mortality.19,21,22 Chang et al.38
reported that obesity per se was not associated with poorer
kidney transplant outcomes, although it was associated with
factors that led to poorer graft and patient survival. Indeed,
patients with a BMI X30 kg/m2 receiving single pediatric
kidneys had better death-censored graft survival rates when
compared with non-obese patients.39 Zaydfudim et al.40
reported that pretransplant overweight and obese status did
not affect physical quality of life after kidney transplantation.
In our study, the association between the pretransplant
BMI and the risk of DGF was rather linear, incremental,
consistent across virtually subgroups, and robust, even after
adjusting for several important confounders. Only few
studies examined the association between BMI and DGF,
and found conflicting or equivocal results. A small case–-
control study (n¼ 80) showed the obese patients have higher
risk of DGF after kidney transplantation,27 whereas Yama-
moto et al.28(n¼ 28) found no association between obesity
and DGF. These studies were likely underpowered and used
inconsistent definitions of DGF.
Several potential mechanisms may contribute to the
observed associations. A biologically plausible explanation
Table 2 |Multivariate logistic regression models showing pretransplant weight and BMI and their ORs and 95% CI for delayed
graft function
Unadjusted Case mix adjusted Case mix and MICS adjusted
Case mix, MICS, and
transplant data adjusted
Pretransplant weight OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Weight (kg; +1 s.d.) 1.29 (1.24–1.35) o0.001 1.32 (1.25–1.39) o0.001 1.33 (1.25–1.41) o0.001 1.34 (1.26–1.44) o0.001
BMI (kg/m2; +1 s.d.) 1.30 (1.24–1.36) o0.001 1.29 (1.23–1.36) o0.001 1.33 (1.26–1.41) o0.001 1.35 (1.27–1.44) o0.001
BMI425 (kg/m2) vs BMIp25 (kg/m2) (ref.) 1.48 (1.44–1.75) o0.001 1.53 (1.38–1.69) o0.001 1.53 (1.37–1.72) o0.001 1.57 (1.39–1.79) o0.001
BMI430 (kg/m2) vs BMIp30 (kg/m2) (ref.) 1.54 (1.39–1.71) o0.001 1.51 (1.35–1.68) o0.001 1.50 (1.33–1.69) o0.001 1.48 (1.30–1.70) o0.001
BMI435 (kg/m2) vs BMIp35 (kg/m2) (ref.) 1.78 (1.53–2.08) o0.001 1.82 (1.55–2.13) o0.001 1.84 (1.53–2.21) o0.001 1.87 (1.52–2.30) o0.001
BMI440 (kg/m2) vs BMIp40 (kg/m2) (ref.) 2.25 (1.72–2.96) o0.001 2.34 (1.77–3.10) o0.001 2.51 (1.80–3.50) o0.001 2.78 (1.88–4.12) o0.001
Abbreviations: BMI, body mass index; CI, confidence interval; MICS, malnutrition–inflammation complex syndrome; OR, odds ratio.
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Figure 2 |Multivariate analysis of logistic regression models
showing pretransplant body mass index (BMI) and odds ratio
(OR, and 95% confidence interval as error bars) of delayed graft
function (DGF) in four different models (reference: BMI 22 to
o25kg/m2). MICS, malnutrition–inflammation complex syndrome;
Tx, transplanted covariates.
Age <50 years
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Presence of diabetes
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Figure 3 |Multivariate analysis of fully adjusted (for case mix,
malnutrition–inflammation complex syndrome, and
transplant covariates) logistic regression models showing
pretransplant body mass index (BMI) and odds ratio (OR, and
95% confidence interval as error bars) of delayed graft
function (DGF) for each standard deviation higher BMI in
different subgroups of patients. EDC, extended donor criteria.
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is that obesity is associated with longer operative time of
longer and warm ischemic time,31 which are per se risk
factors of DGF.32,33 Obesity is associated with high
sympathetic activity,29,30 which results in renal vasoconstric-
tion. Moreover, the prompt administration of calcineurin
inhibitors after transplantation, probably in higher doses
given to overweight or obesity, may aggravate vasoconstric-
tion and further compromise graft perfusion, increasing the
risk of DGF. Another potential explanation is the linkage
between obesity and increased prothrombotic activity and
endothelial dysfunction.41 Body fat mass, in particular central
obesity, is associated with higher levels of thrombin
generation.42,43 Obesity is also a risk factor for venous
thromboembolic disease.44 Increased prothrombotic activity
and endothelial dysfunction may contribute to the risk of
graft microthrombosis,45 which per se may have an important
role in DGF.46
There are potential limitations to our study. Like all
observational studies, our study too cannot prove causality.
Patients who were excluded from analyses were likely
different from the included ones, but their proportion was
relatively small. In the SRTR data set, more detailed data
about immunosuppression therapy such as calcineurin
inhibitor dose or blood level or the induction therapy, which
may also have an effect on the risk of DGF, do not exist.
Additional limitation is the uncertainty about the use of BMI
as a measure of obesity. BMI per se may not be an appropriate
measure to characterize nutritional status, body composition,
obesity, or muscle mass in dialysis patients.47–52 To better
characterize nutritional status, additional parameters such as
waist circumference would be needed.48,50–52 To the best of
our knowledge, our study is the first examining the
association between pretransplant BMI and immediate
post-transplant DGF in such a large and nationally
representative patient population. Other strengths of our
study include the high number of patients, the multilevel
adjustments including for laboratory data, and the con-
temporary nature of the cohort (2001–2007).
CONCLUSIONS
In our large and contemporary national cohort of 11,836
kidney transplant recipients, pretransplant BMI is associated
with risk of DGF, even after extensive multivariate adjust-
ment. The association between pretransplant BMI and DGF
was consistent in all examined subgroups. Despite data
indicating an obesity paradox with greater survival of
overweight and obese hemodialysis patients,47,49,53,54 careful
trials of closely supervised weight reduction may be needed
to examine whether immediate post-transplant outcomes
including risk of DGF can be improved.
MATERIALS AND METHODS
Patients
We linked data on all kidney transplant recipients listed in the SRTR
up until June 2007 to a list of individuals with chronic kidney
disease stage 5D, who underwent maintenance hemodialysis
treatment from July 2001 to June 2006 in one of the outpatient
dialysis facilities of a US-based large dialysis organization (DaVita
Inc, before its acquisition of former Gambro dialysis facilities). The
study was approved by the institutional review committees of both
Los Angeles Biomedical Research Institute at Harbor-UCLA and
DaVita Clinical Research. The study was conforming to the
principles of the Declaration of Helsinki. Because of the large
sample size, the anonymity of the patients studied and the non-
intrusive nature of the research, the requirement for informed
consent was waived.
Clinical and demographic measures
The creation of the national DaVita maintenance hemodialysis
patient cohort has been described previously.51,54–57 Demographic
data and details of medical history were collected, including
information on age, gender, race, type of insurance, marital status,
presence of diabetes, height, post-hemodialysis dry weight (to
calculate average BMI), and dialysis vintage. Dialysis vintage was
defined as the duration of time between the first day of dialysis
treatment and the day of kidney transplantation.
To minimize measurement variability, all repeated measures for
each patient during any given calendar quarter, that is, over a 13-
week or 3-month interval, up to the time of kidney transplantation,
were averaged and the quarterly means in each of the 20 calendar
quarters were used in our analyses. Each patient had up to 39
recoded post-hemodialysis weights, corresponding thrice weekly
maintenance hemodialysis treatment. All values were averaged into
one single quarterly value per patient per each calendar quarter. In
the present study, we used the average of a number of BMI
measurement in the last quarter before transplantation.
After deleting extreme outliers (BMIo12 or 460 kg/m2), we
divided pretransplant BMI into six a priori selected categories or
underweight (p19.99 kg/m2), low normal weight (20–21.99 kg/m2),
high normal weight (22–24.99 kg/m2) overweight (25–29.99 kg/m2),
mild obesity (30–34.99 kg/m2), and moderate-to-sever obesity
(X35 kg/m2). These increments were consistent with our previous
studies.58
Laboratory measures
Blood samples were drawn using uniform techniques in all of the
DaVita dialysis clinics and were transported to the DaVita
Laboratory in Deland, Florida, typically within 24 h. All laboratory
values were measured by automated and standardized methods in
the DaVita Laboratory. Most laboratory values were measured
monthly, including serum urea, creatinine, albumin, calcium,
phosphorus, bicarbonate, and total iron-binding capacity. Serum
ferritin was measured at least quarterly. Hemoglobin was measured,
at least, monthly in essentially all patients and weekly to biweekly in
most patients. Most blood samples were collected before dialysis,
with the exception of the postdialysis serum urea nitrogen that was
obtained to calculate urea kinetics. Kt/V (single pool) was calculated
using urea kinetic modeling equations, as described elsewhere.56
Albumin-corrected calcium was calculated by subtracting 0.8mg/dl
for each g/dl serum albumin below 4.0 g/dl.59
Definition of DGF
DGF was defined as the need for any dialysis therapy in the first
week after transplantation.1
Statistical methods
Data were summarized using proportions, means (±s.d.), or
medians (interquartile range), as appropriate. Categorical variables
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were analyzed with w2-tests, and continuous variables were compared
using Student’s t-tests or Mann–Whitney U-tests, Kruskal–Wallis H
tests or analysis of variance, as appropriate. In all statistics, two-sided
tests were used and the results were considered statistically
significant if P-value was o0.05. Logistic regression models were
employed to estimate the OR (and 95% CI) of post-transplant DGF
based on pretransplant BMI during the calendar quarter preceding
the kidney transplantation.
For each analysis, four models were examined based on the level
of multivariate adjustment: (I) an unadjusted model; (II) case mix
adjusted models included age, gender, race ethnicity (African
Americans and other self-categorized blacks, non-Hispanic whites,
Asians, Hispanics, and others), diabetes mellitus, dialysis vintage,
primary insurance (Medicare, Medicaid, private, and others), marital
status (married, single, divorced, widowed, and other or unknown),
the standardized mortality ratio of the dialysis clinic during entry
quarter, dialysis dose as indicated by Kt/V (single pool), and presence
or absence of a dialysis catheter; (III) malnutrition–inflammation
complex syndrome-adjusted models, which included all of the
covariates in the case mix model as well as 11 surrogates of
nutritional status and inflammation, including 10 laboratory
variables with known association with clinical outcomes in HD
patients, that is, normalized protein catabolic rate as an indicator of
daily protein intake, also known as the normalized protein nitrogen
appearance,60 serum or blood concentrations of albumin, creatinine,
total iron-binding capacity, ferritin, phosphorus, calcium, bicarbo-
nate, peripheral white blood cell count, lymphocyte percentage, and
hemoglobin; and (IV) case mix, malnutrition–inflammation complex
syndrome, and transplant data-adjusted models included all of the
above plus seven transplant-related variables: (1) donor type
(deceased or living), (2) donor age, (3) panel reactive antibody titer
(last value before transplant), (4) number of human leukocyte
antigen mismatches, (5) cold ischemia time, (6) transfusion before
transplantation, and (7) extended donor criteria using standard
definition (donor history of hypertension and/or serum creatinine of
donor 41.5mg/dl and/or cause of death in donor is a cerebrovas-
cular event).
In sensitivity analyses, we reexamined all associations after 1962
peritoneal dialysis patients were added to 11,836 hemodialysis
patients, leading to a total sample size of 13,798 kidney-transplanted
recipients. Missing covariate data in the last (pretransplant) calendar
quarter were imputed by medians or means including from prior
calendar quarters, as appropriate. All analyses were carried out using
STATA version 11.1 (STATA Corporation, College Station, TX).
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SUPPLEMENTARY MATERIAL
Table S1. Multivariate analysis of fully adjusted (for case mix,
malnutrition–inflammation complex syndrome, and transplant
covariates) logistic regression models showing pretransplant body
mass index (BMI) and odds ratio (OR, and 95% confidence interval (CI)
as error bars) of delayed graft function (DGF) for each standard
deviation higher BMI in different subgroups of patients.
Figure S1. Multivariate analysis of logistic regression models
showing pretransplant BMI and OR (and 95% CI as error bars) of DGF
in our fully adjusted models using cubic spline curve in 11,836
kidney-transplanted patients.
Figure S2. Multivariate analysis of logistic regression models
showing pretransplant BMI and OR (and 95% CI as error bars) of DGF
in four different models (reference: BMI 22 too25 kg/m2; A) and the
fully adjusted model using cubic spline curve (B) in 13,798 kidney-
transplanted patients.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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